Research
We address cellular function and have developed methodologies to address
directly how proteins act in situ. In order to address this, we developed
a novel technique called Chromophore-Assisted Laser Inactivation (CALI)
to inactivate specific proteins in living cells and embryos at precise
times and locations. We have ascertained the spatial specificity of CALI
and established the physical basis of its mechanism. We have also developed
micro-CALI which focuses the laser through microscope optics to inactivate
specific protein functions in single cells with a spatial resolution of
a few microns. These approaches are complementary to existing knockout
strategies and offer several advantages including an unprecedented degree
of spatial and temporal resolution, lack of genetic compensation and the
ability to target proteins in cells and tissues that are not amenable
to genetic approaches.
One major question addressed by the lab is what are the molecular mechanisms
that determine how the nervous system is formed during embryonic development?
One long-term goal of our lab is to elucidate the pathways of molecular
interactions of axon guidance from the external environment to the cytoskeleton.
These pathways are made up of membrane receptors, signal transduction
molecules and cytoskeletal proteins that must act together to translate
extracellular cues into directed motility. These techniques have been
applied to a large variety of proteins inside growth cones and we have
ascertained the functional roles of many of these proteins in growth cone
motility and guidance. These include: calcineurin; myosin I b and V; talin;
vinculin; ezrin; radixin; tau; NCAM-180; L1; ephrin-A5, GAP-43; protein
kinase C and zyxin.
Our most recent work is directed at discovering proteins involved in
cancer cell invasion using CALI and functional genomics. Our previous
work has addressed the molecular mechanisms growth cone motility. Motility
is also critical for how cancer cells invade. We have now applied CALI
to cancer relevant proteins to address their cellular roles and have studied
ezrin, pp60-c-src; pp59-fyn, and TSC I (hamartin). We have begun to use
CALI with antibody libraries in a high throughput and automated fashion
to discover new proteins that act in cancer cell invasiveness. We have
initiated this high-throughput screen and begun to identify and validate
targets. This will be the first proteome-wide screen for target validation
that directly addresses cellular function. It has clinical importance
as CALI provides a means of identifying and validating such proteins as
targets for drug discovery and novel anti-cancer therapeutics.
Click here
to see a QuickTime movie of ezrin inactivation by CALI
Click here
for a list of publications
The FALI/CALI Inactivation Strategy
HTS screen to identify proteins involved in metastasis
|